| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014181137 |
| Title |
Novel Histone Deacetylase Inhibitors. |
| Abstract |
The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors. |
| Applicant(s) |
Karus Therapeutics Ltd |
| Representative Drug(s) |
D01JPM |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0SO8W
|
Drug Info
|
N.A.
|
[1] |
|
3
|
D0T7RJ
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2010009166 |
| Title |
Oxindolyl Inhibitor Compounds. |
| Abstract |
A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. (Formula should be inserted here) Formula (I). |
| Applicant(s) |
Gilead Sciences, Inc |
| Representative Drug(s) |
D02KWX |
Drug Info
|
IC50 = 64 nM |
[2] |
| Patent ID |
WO2010009155 |
| Title |
Fused Heterocyclyc Inhibitors of Histone Deacetylase and/or Cyclin-Dependent Kinases. |
| Abstract |
The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. Formula (I). |
| Applicant(s) |
Gilead Sciences, Inc |
| Representative Drug(s) |
D06QPW |
Drug Info
|
IC50 = 20 nM |
[2] |
| Patent ID |
WO2014071000 |
| Title |
Class of Hdac Inhibitors Expands The Renal Progenitor Cells Population and Improves The Rate of Recovery From Acute Kidney Injury. |
| Abstract |
Compounds and compositions are provided that inhibit histone deacylase activity and which expand renal progenitor cell populations and improve kidney function in a damaged kidney. Methods of use of the compounds and compositions are provided. |
| Applicant(s) |
University of Pittsburgh - of the Commonwealth System of Higher Education |
| Representative Drug(s) |
D0TT4A |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014023754 |
| Title |
Compounds for Use In The Treatment of Disorders That Are Ameliorated By Inhibition of Hdac. |
| Abstract |
The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for usein the treatment of disorders that are ameliorated by inhibition of HDACsuch ascancer and hemoglobinopathieslike gama-thalassemia or sickle cell anemia. |
| Applicant(s) |
IRBM - SCIENCE PARK S.P.A |
| Representative Drug(s) |
D0RF1Z |
Drug Info
|
N.A. |
[1] |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US6428983 |
| Title |
Histone Deacetylase As Target For Antiprotozoal Agents. |
| Abstract |
Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections. |
| Applicant(s) |
Merck Co Inc |
| Representative Drug(s) |
D01LDP |
Drug Info
|
N.A. |
Click to Show More |
[3] |
|
2
|
D0H2UJ
|
Drug Info
|
N.A.
|
[3] |
